Estudo KPMNG de Terapia Guiada por Perfil Molecular Baseado em Alterações Genômicas em Tumores Sólidos Avançados II (KOSMOSII)
Estudo do Korean Precision Medicine Networking Group sobre terapia guiada por perfis moleculares baseada em alterações genômicas em tumores sólidos avançados II
A national, prospective, multi-center, open-label, multi-cohort study comprised of a framework to screen patients for actionable targets and evaluation of molecular profiling guided therapy recommended by MTB based on genomic alterations using targeted and/or immunotherapies outside of the approved indications via local clinical practice (Tier 1 & 2) and clinical trials (Tier 3)
Visão geral do estudo
Status
Descrição detalhada
A. The KOSMOS-II study will recruit locally advanced or metastatic solid tumor patients who had disease progression on standard first line anti-cancer treatment and/or has no standard treatment option, in order to prove MTB value to guide treatment within local clinical practice.
B. After site physicians confirm that NGS results of patients are available, they preliminarily decide initial treatment before MTB submission and collect informed consent form, and then patients can register to the KOSMOS-II study. Site physicians upload patients' clinical, pathologic, and genomic data for MTB submission. If site physician cannot determine initial treatment before MTB, site physician can record 'initial treatment cannot be determined' and can register the patient for MTB.
C. MTB records its treatment recommendations within available drugs list based on uploaded data, then site physicians make a final treatment decision, after informing patient about MTB decision and assessment of patients' final health status and preference.
D. Patients who have insufficient genomic information from their NGS results (e.g., lack of variant calling format file or uninterpretable reports) or who are candidates of immunotherapy will submit their tissue and/or blood, for central NGS testing and exploratory biomarker analysis.
E. Recommended treatment option There are three different options including (1) Tier 1: Therapeutic use of investigational products (KOSMOS-II drugs), (2) Tier 2: alternative treatment options, and (3) Tier 3: clinical trials
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
-
Bucheon-si, Coréia do Sul
- Soonchunhyang University Hospital Bucheon
-
Chungju, Coréia do Sul
- Chungbuk National University Hospital
-
Daegu, Coréia do Sul
- Keimyung University Dongsan Hospital
-
Daegu, Coréia do Sul
- Kyungpook National University Chilgok Hospital
-
Daegu, Coréia do Sul
- Yeungnam University Medical Center
-
Daejeon, Coréia do Sul
- Chungnam National University Hospital
-
Goyang, Coréia do Sul
- National Cancer Center
-
Hwasun, Coréia do Sul
- Chonnam National University Hwasun Hospital
-
Incheon, Coréia do Sul
- Gachon University Gil Medical Center
-
Incheon, Coréia do Sul
- The Catholic University of Korea, Incheon St. Mary's Hospital
-
Jeonju, Coréia do Sul
- Jeonbuk National University Hospital
-
Jinju, Coréia do Sul
- Gyeongsang National University Hospital
-
Pusan, Coréia do Sul
- Dong-A University Hospital
-
Seongnam, Coréia do Sul
- Cha University Bundang Medical Center
-
Seongnam, Coréia do Sul
- Seoul National University Bundang Hospital
-
Seoul, Coréia do Sul
- Asan Medical Center
-
Seoul, Coréia do Sul
- Korea University Anam Hospital
-
Seoul, Coréia do Sul
- Korea University Guro Hospital
-
Seoul, Coréia do Sul
- Samsung Medical Center
-
Seoul, Coréia do Sul
- Seoul National University Hospital
-
Seoul, Coréia do Sul
- The Catholic University of Korea, Yeouido St. Mary's Hospital
-
Seoul, Coréia do Sul
- Gangbuk Samsung Hospital
-
Seoul, Coréia do Sul
- Hanyang University Hospital
-
Seoul, Coréia do Sul
- Chung-ang University Hospital
-
Seoul, Coréia do Sul
- Ewha womans university Mokdong Hospital
-
Seoul, Coréia do Sul
- The Catholic University of Korea, Seoul ST. Mary's Hospital
-
Seoul, Coréia do Sul
- Yonsei Cancer Hospital
-
Suwon, Coréia do Sul
- Ajou University Hospital
-
Suwon, Coréia do Sul
- The Catholic University of Korea, ST. Vincent's Hospital
-
Ulsan, Coréia do Sul
- Ulsan University Hospital
-
Wŏnju, Coréia do Sul
- Wonju Severance Christian Hospital
-
Yangsan, Coréia do Sul
- Pusan National University Yangsan Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Histologically proven locally advanced or metastatic solid tumor patients with disease progression on standard first line anti-cancer treatment and/or has no standard treatment option
Descrição
Inclusion Criteria:
-
19 years of age or older
-
Histologically proven locally advanced or metastatic solid tumors*** who showed disease progression on standard first line anti-cancer treatment and/or has no standard treatment option
*** very rare diseases without standard treatment option which form solid mass, such as Erdheim Chester disease can be enrolled after KOSMOS MTB approval
-
A genomic test results must be available in a MFDS-accredited for laboratories offering service, or in part of clinical trial/study or other commercial labs approved and certified by regulatory bodies compatible with MFDS, such as CLIA. A genomic test can be conducted with tumor tissue as well as plasma circulating tumor DNA.
- Results from genomic profiling tests performed after diagnosis with metastatic/advanced disease to registration are acceptable. NGS results performed within three years prior to registration are preferred. Those patients with NGS results from primary tumor or more than 3 years prior to enrollment can be registered and whether NGS data is acceptable will be subject to MTB decision.
- NGS panels should be i. Tested in a lab that is accredited by one or more quality assurance program (e.g., Korean Institute of Genomic Testing Evaluation, The Korean Society of Pathologists, Korean Society for Laboratory Medicine, Korea Laboratory Accreditation Scheme, etc.) ii. Patients who have insufficient genomic information from their NGS results (e.g., lack of variant calling format file or uninterpretable reports) or who are candidates of immunotherapy will submit their tissue and/or blood, for central NGS testing and exploratory biomarker analysis.
-
Ability to understand and the willingness to sign a written informed consent document
-
Life expectancy of at least 12 weeks
-
Adequate recovery from most recent systemic or local treatment for cancer.
Exclusion Criteria:
- Patients receiving any anti-cancer treatment (local treatment, chemotherapy, immunotherapy, targeted therapy) within 2 weeks prior to the start of study treatment
- Any clinical condition, according to the opinion of site physicians, which makes molecular profiling guided therapy not at the best interest of the participating patient.
- Patients who have ongoing toxicities of ≥ CTCAE 2, other than peripheral neuropathy, related to previous anti-cancer treatment. Patients with ongoing peripheral neuropathy of ≥ CTCAE 3 will be excluded. Laboratory abnormalities ≥ CTCAE 2 considered as not clinically significant by the study physician will be allowed.
- Pregnant or breastfeeding, or intending to become pregnant during the study
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Tier 1. Therapeutic use of investigational products (KOSMOS-II drugs)
If there are no drugs available under current regulation or patients are not feasible to any clinical trials, and If tumors have actionable genetic alterations and approved drug in any indications but tumor type is not indicative, the MTB may recommend one of KOSMOS-II drugs, therapeutic use of investigational products. |
ALK fusion or mutations, Mutations or amplification in any of the following: RET
Outros nomes:
MSI high status by any method Or Any mutation in any of these genes: MLH1 or MSH2 or MSH6 or PMS2 or EPCAM Or Any of the following mutations in POLE: R150X, P286R, P286H, S297F, Y298fs, F367S, V411, L424V, P436R, S459F, R665W, L698fs, R762W, R1519C, R1826W, D316H, D316G, R409W, L474P Or Any of the following mutations in POLD1: P112fs, A930fs, S478N Or Any mutation in the following: POLE not listed above, POLD1 not listed above, POLD2, POLD3, POLD4, POLQ or PRKDC Or Any loss of function mutations in BRCA1, BRCA2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1, RFC2, RFC3, RFC4, RFC5, PCNA, RPA1, PRA2, PRA3, PRA4, or SSBP1 High tumor mutational burden decided by KOSMOS-II MTB (TMB ≥20/Mb in local NGS or if 10-20/Mb, confirmed by central NGS te sting)
Outros nomes:
EGFR Exon 19 deletions in the region E746_E759; Any of the following EGFR mutations: E709A, E709G, E709K, E884K, G719A, G719C, G719S, L858R, L861Q, L833V, S768I
Outros nomes:
ERBB2 amplification, or over-expression; or presence of any of the following ERBB2 mutations: G309A, G309E, S310F, S310Y, R678Q, I655V, D769H, D769Y, L755S, p.L75 5_T759del, I767M, V777L, E321G, R896C; P780ins; delL755-T759 ERBB2 amplification or approved by the KOSMOS Molecular Tumor Board
Outros nomes:
ERBB2 amplification, or over-expression; or presence of any of the following ERBB2 mutations: G309A, G309E, S310F, S310Y, R678Q, I655V, D769H, D769Y,L755S, p.L75 5_T759del, I767M, V777L, E321G, R896C; P780ins; delL755-T759 ERBB2 oncogenic mutations; G152V, X215_splice, D277Y, G292C, N302K, V308M, G309A, S310F, S310Y, S244C, L651V, V659E, G660D, R678Q, V697L, G727A, T733I, L755A, L755P, L755S, D769H, D769Y, A775_G776insSVMA, A775_G776insYVMA (i.e.,Y772_A775dup,M774_A775insAYVME 770delinsEAYVM), G776_V777 > AVCV, G776_V777 > AVGCV, G776_V777 > VCV, G776_V777insVC, G776C, G776delinsLCT, G776L, G776dleinsVC, G776L777_G778insC, V777L, V777M, G778_Y779insGSP, P780_Y781insGSP (i.e.,G778_P780dup), L786V, N813D, R840W, V842I, T862A, R896G, E1021Q or approved by the KOSMOS Molecular Tumor Board
Outros nomes:
BRAF_V600E/D/K/R mutations
Outros nomes:
FH inactivating mutations or approved by the KOSMOS Molecular Tumor Board
Outros nomes:
ROS1 gene fusion using either a fluo rescence in situ hybridization (FISH) or next-generation sequencing (NGS) or approved by the KOSMOS Molecular Tumor Board
Outros nomes:
RET fusion or mutations; CCDC6 RET, RET V804L, RET V804M, RET M918T, KIF5B-RET, RET C634W or approved by the KOSMOS Molecular Tumor Board
Outros nomes:
|
|
Tier 2: Alternative treatments
If there are no KOSMOS-II drugs (Tier 1) or clinical trials (Tier 3) appropriate for patients, the MTB may recommend alternative treatment options (e.g., conventional therapy, radiotherapy, or supportive care). |
|
|
Tier 3: Clinical trial
If patient is eligible for clinical trials matched for actionable genomic alterations found in NGS testing, the MTB will recommend enrollment to clinical trials. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
To evaluate the feasibility of molecular profiling guided therapies (MGT) based on genomic alterations in patients with advanced solid tumors in terms of the proportion of receipt of the treatment
Prazo: 12 months after treatment initiation (estimated average)
|
Percentage of patients who receive molecular profiling guided therapy as recommended by MTB, either in therapeutic use of investigational products (KOSMOS-II drugs), alternative treatment, or clinical trial. |
12 months after treatment initiation (estimated average)
|
|
To evaluate the effectiveness of molecular profiling guided therapies in terms of clinical benefit rate (CR/PR/SD beyond 16 +/- 2 weeks) in Tier 1* population
Prazo: Assessed at 16 weeks of treatment
|
Percentage of patients achieving response defined as CR/PR/SD at 16 ± 2 weeks reported by site physician |
Assessed at 16 weeks of treatment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Objective response rate
Prazo: 12 months after treatment initiation (estimated average)
|
The proportion of patients who obtained CR/PR as the best response according to the RECIST 1.1 criteria |
12 months after treatment initiation (estimated average)
|
|
Progression-free survival
Prazo: 12 months after treatment initiation (estimated average)
|
Progression-free survival in accordance with local clinical practice |
12 months after treatment initiation (estimated average)
|
|
Treatment duration
Prazo: 12 months after treatment initiation (estimated average)
|
The period from the start of treatment to the end of treatment for any reason |
12 months after treatment initiation (estimated average)
|
|
1-year overall survival rate
Prazo: 12 months after treatment initiation (estimated average)
|
Proportion of patients alive 1 year after study registration |
12 months after treatment initiation (estimated average)
|
|
To evaluate safety of molecular profiling guided therapies
Prazo: 12 months after treatment initiation (estimated average)
|
The incidence of serious adverse events will be calculated among the adverse events in patients with Tier 1 and Tier 3. ( based on NCI-CTCAE v5.0 ) |
12 months after treatment initiation (estimated average)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: JEEHYUN KIM, Seoul National University Bundang Hospital
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Processos Patológicos
- Neoplasias
- Processos Neoplásicos
- Condições Patológicas, Sinais e Sintomas
- Neoplasia Metástase
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Compostos de enxofre
- Produtos químicos orgânicos
- Compostos heterocíclicos
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Compostos policíclicos
- Amidas
- Indoles
- Anticorpos, monoclonais, humanizados
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Macrolídeos
- Lactonas
- Lactamas, macrocíclicas
- Compostos macrocíclicos
- Sulfonamidas
- Sulfonas
- Quinazolines
- Maytansine
- Trastuzumabe
- Cloridrato De Erlotinibe
- Bevacizumabe
- Ado-Trastuzumabe Emtansina
- Vemurafenibe
- Pertuzumab
- Atezolizumab
- Entrectinib
- Alectinib
- Pralsetinibe
Outros números de identificação do estudo
- KCSG AL 22-09
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .